Troriluzole Prodrug Dosing for Spinocerebellar Ataxia 3
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are currently no U.S. Food and Drug Administration (FDA) approved medications for the treatment of Spinocerebellar Ataxia Type 3 (SCA3), and existing treatments like riluzole require longer studies and disease-specific trials to confirm their effectiveness.
Innovation Solution
A prodrug of riluzole, known as troriluzole, is developed for the treatment of SCA3, offering improved dosing regimens and administration forms to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If riluzole is used to treat SCA3, then therapeutic effect is improved, but treatment duration and study period are extended
Solution Approach 1:
The patent modifies the chemical structure of riluzole by introducing a trifluoromethoxy group at the 6-position of the benzothiazole ring, creating troriluzole. This structural parameter change improves metabolic stability and extends half-life, allowing for more effective treatment within a reasonable study period while maintaining therapeutic efficacy
2Adaptability or versatility
If no FDA approved medication is available for SCA3, then treatment options are limited, but development of new treatments requires extensive clinical trials
Solution Approach 1:
The patent performs preliminary chemical modification of riluzole to create troriluzole with improved pharmacokinetic properties before clinical testing. The preclinical studies demonstrate enhanced metabolic stability and neuroprotection in animal models of SCA3, providing a stronger foundation for clinical trial approval and reducing the overall development timeline
Data Source
AI summary
Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.